Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Esperion Theraptc (ESPR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,205,464
  • Shares Outstanding, K 26,800
  • Annual Sales, $ 0 K
  • Annual Income, $ -166,990 K
  • 36-Month Beta 2.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 7.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -1.58
  • Number of Estimates 6
  • High Estimate -1.43
  • Low Estimate -1.73
  • Prior Year -1.86
  • Growth Rate Est. (year over year) +15.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.13 +12.09%
on 09/24/18
50.26 -10.51%
on 10/17/18
-0.59 (-1.29%)
since 09/19/18
3-Month
40.13 +12.09%
on 09/24/18
54.39 -17.30%
on 08/27/18
+1.85 (+4.29%)
since 07/19/18
52-Week
33.06 +36.06%
on 05/03/18
82.68 -45.60%
on 02/27/18
-2.65 (-5.56%)
since 10/19/17

Most Recent Stories

More News
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion (NASDAQ: ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with...

ESPR : 44.98 (-6.78%)
New Research Coverage Highlights Esperion Therapeutics, Summit Therapeutics, Ocwen Financial, Keane Group, Cellectis S.A, and Rapid7 -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Esperion Therapeutics, Inc....

ESPR : 44.98 (-6.78%)
CMVLF : 27.9900 (+7.49%)
SMMT : 1.88 (+1.62%)
RPD : 32.53 (-4.04%)
OCN : 3.98 (+3.65%)
FRAC : 12.18 (-0.25%)
CLLS : 26.20 (-2.86%)
Notable Tuesday Option Activity: ESPR, CATM, NAV

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Esperion Therapeutics Inc , where a total volume of 11,953 contracts has been traded...

ESPR : 44.98 (-6.78%)
Do Options Traders Know Something About Esperion (ESPR) Stock We Don't?

Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately.

ESPR : 44.98 (-6.78%)
Esperion Therapeutics is Now Oversold (ESPR)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

ESPR : 44.98 (-6.78%)
Are Options Traders Betting on a Big Move in Esperion (ESPR) Stock?

Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately.

ESPR : 44.98 (-6.78%)
Esperion (ESPR) Combination Regimen Lowers Bad Cholesterol

Esperion Therapeutics' (ESPR) combination regimen of bempedoic acid and Merck's Zetia achieves significant reduction in bad cholesterol in a phase III study.

ESPR : 44.98 (-6.78%)
ENDP : 17.53 (-0.06%)
MRK : 72.35 (+0.19%)
BSTC : 62.49 (+1.44%)
Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of Bempedoic Acid at the European Society of Cardiology Congress

-- Bempedoic Acid Achieved Additional 20% On-Treatment LDL-C Lowering on Background of Maximally Tolerated Statins --

ESPR : 44.98 (-6.78%)
Are Options Traders Betting on a Big Move in Esperion (ESPR) Stock?

Investors in Esperion (ESPR) need to pay close attention to the stock based on moves in the options market lately.

ESPR : 44.98 (-6.78%)
Market Trends Toward New Normal in Esperion Therapeutics, Oxford Immunotec Global, Limoneira, R1 RCM, Carbonite, and Shenandoah Telecommunications -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Esperion Therapeutics, Inc....

ESPR : 44.98 (-6.78%)
CARB : 35.03 (-2.61%)
OXFD : 15.94 (-2.63%)
LMNR : 24.80 (-0.56%)
SHEN : 38.43 (+0.60%)
RCM : 8.58 (+1.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade ESPR with:

Business Summary

Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.

See More

Key Turning Points

2nd Resistance Point 51.89
1st Resistance Point 48.43
Last Price 44.98
1st Support Level 43.06
2nd Support Level 41.15

See More

52-Week High 82.68
Fibonacci 61.8% 63.73
Fibonacci 50% 57.87
Fibonacci 38.2% 52.01
Last Price 44.98
52-Week Low 33.06

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar